• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Oasmia Pharmaceutical AB

+ Add to Watchlist


1.939 EUR 0.016 0.83%

As of 12:59:35 ET on 12/17/2014.

Snapshot for Oasmia Pharmaceutical AB (OMAX)

Open: 1.867 Day's Range: 1.867 - 1.981 Volume: 0
Previous Close: 1.923 52wk Range: 1.867 - 3.320 1-Yr Rtn: -9.45%

Stock Chart for OMAX

No chart data available.
  • OMAX:GR 1.975
  • 1D
  • 1M
  • 1Y
Interactive OMAX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OMAX

Current P/E Ratio (ttm) -
Estimated P/E(04/2015) 96.6401
Relative P/E vs. DAX -
Earnings Per Share (SEK) (ttm) -
Est. EPS (SEK) (04/2015) 0.1900
Est. PEG Ratio -
Market Cap (M EUR) 189.75
Shares Outstanding (M) 97.86
30 Day Average Volume 12
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OMAX

  • Revenue
  • Net Income (M/SEK)
  • Profit Margin (%)

Company Profile & Key Executives for OMAX

Oasmia Pharmaceutical AB is a pharmaceutical company that specializes in human and veterinary oncology. The Company's develops the semi-synthesized substances for different therapeutic areas, primarily for anti-cancer chemotherapy. Oasmia also conducts research within antibiotics, asthma and neurologically targeted drugs in clinical or preclinical stages.

Joel Tomas CitronChairmanJulian AleksovPresident/CEO/Co-Founder
Anders BlomExec Vice PresidentMargareta ErikssonVP:Clinical Development
More Company Profile & Key Executives for OMAX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil